HLA-DRB1∗15 influences the development of brain tissue damage in early PPMS

Neurology

Volumn 83, Issue 19, 2014, Pages 1712-1718

  Tur, Carmen ^a,c   Ramagopalan, Sreeram ^d   Altmann, Daniel R ^b,e   Bodini, Benedetta ^a   Cercignani, Mara ^f,g   Khaleeli, Zhaleh ^a   Miller, David H ^b   Thompson, Alan J ^a   Ciccarelli, Olga ^a  

^a Departments of Brain Repair and Rehabilitation   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^g and University of Bristol   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN; HLA-DRB1*15 ANTIGEN;

ADULT; ALLELE; ARTICLE; BRAIN DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SPINAL CORD LESION; WHITE MATTER; BRAIN; GENETICS; LONGITUDINAL STUDY; PATHOLOGY; SPINAL CORD;

ADULT; BRAIN; DISEASE PROGRESSION; FEMALE; GRAY MATTER; HLA-DRB1 CHAINS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SPINAL CORD; WHITE MATTER;

EID: 84918569913     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000959     Document Type: Article

References (22)

1. Compston A, Howard S. HLA typing in multiple sclerosis. Lancet 1982;2:661.
2. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000;48: 211-219.
3. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
4. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype- phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009;132:250-259.
5. DeLuca GC, Alterman R, Martin JL, et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology. Brain 2013;136: 1025-1034.
6. Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O, Miller DH, Thompson AJ. Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 2008;65:1454-1459.
7. Tur C, Khaleeli Z, Ciccarelli O, et al. Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS. J Neurol Neurosurg Psychiatry 2011;82:423-428.
8. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003;126:2528-2536.
9. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
11. Ramagopalan SV, Morris AP, Dyment DA, et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 2007;3:1607-1613.
12. Tur C, Penny S, Khaleeli Z, et al. Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis. Mult Scler 2011;17:1324-1332.
13. Barker GJ, Tofts PS, Gass A. An interleaved sequence for accurate and reproducible clinical measurement of magnetization transfer ratio. Magn Reson Imaging 1996;14:403-411.
14. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-708.
15. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56:407-415.
16. Moll NM, Rietsch AM, Thomas S, et al. Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol 2011;70:764-773.
17. Chen JT, Easley K, Schneider C, et al. Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology 2013;80:246-252.
18. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol Epub 2013 Dec 14.
19. Sombekke MH, Lukas C, Crusius JB, et al. HLA-DRB1∗1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009;66: 1531-1536.
20. Jiang J, Sachdev P, Lipnicki DM, et al. A longitudinal study of brain atrophy over two years in community-dwelling older individuals. Neuroimage 2014;86: 203-211.
21. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-1238.
22. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.